Rwy'n croesawu penderfyniad yr Uchel Lys ar ddydd Gwener 21 Medi, yn gwrthod cais gan ddau gwmni fferyllol am adolygiad barnwrol i herio polisi 12 Grŵp Comisiynu Clinigol yn Lloegr oedd yn cynnig bevacizumab fel opsiwn cyffredinol ar gyfer trin dirywiad macwlaidd gwlyb sy’n gysylltiedig â henaint.
I welcome the decision made by the High Court on Friday 21 September, dismissing an application for judicial review by two pharmaceutical companies to challenge the policy of 12 Clinical Commissioning Groups in England which offered bevacizumab (Avastin®) as an option for the routine treatment of wet age-related macular degeneration (wet AMD).